ReviewWorld journal of gastroenterology2018
Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- IBDTransDB: a manually curated transcriptomic database for inflammatory bowel disease.Database : the journal of biological databases and curation · 2024Pooled it
- Association between vedolizumab and postoperative complications in IBD: a systematic review and meta-analysis.International journal of colorectal disease · 2021Pooled it
- Predictive Utility of the Vedolizumab Clinical Decision Support Tool in a Real-World IBD Cohort: Differential Performance in Crohn's Disease and Ulcerative Colitis.Medicina (Kaunas, Lithuania) · 2026Article
- Upadacitinib and vedolizumab combination therapy for the management of refractory ulcerative colitis and Crohn's disease.Intestinal research · 2025Article
- Biosimilars versus biological therapy in inflammatory bowel disease: challenges and targeting strategies using drug delivery systems.Clinical and experimental medicine · 2025Review
- Optimal Management of Patients with Moderate-to-Severe Inflammatory Bowel Disease.Journal of clinical medicine · 2024Review
- Predictors of the efficacy of vedolizumab in patients with ulcerative colitis.Nagoya journal of medical science · 2024Observational
- Novel Pharmaceuticals and Therapeutics for Tumor Necrosis Factor-Alpha-Resistant Crohn's Disease: A Narrative Review.Cureus · 2024Review
- Case report: Vedolizumab in Oral Crohn's disease: the downsides of a gut-specific therapy for a multi-site disease.Frontiers in medicine · 2024Article
- The Efficacy and Safety of Biologic Drugs in the Treatment of Moderate-Severe Crohn's Disease: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Lung Nodules in a 24-Year-Old Male with Crohn's Disease.Journal of general internal medicine · 2023Article
- Accelerating the Evolution of Immune-Related Enterocolitis Management.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Article
- Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis.Journal for immunotherapy of cancer · 2023Article
- Mycobiome and Inflammatory Bowel Disease: Role in Disease Pathogenesis, Current Approaches and Novel Nutritional-based Therapies.Inflammatory bowel diseases · 2023Review
- The multifunctional nature of CD103 (αEβ7 integrin) signaling in tissue-resident lymphocytes.American journal of physiology. Cell physiology · 2022Review
- Treatment and Management of Chronic Inflammatory Bowel Diseases: Optimizing Present and Future Therapeutic Choices.Journal of clinical medicine · 2022Article
- Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study.Journal of personalized medicine · 2022Article
- Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort.Digestive diseases and sciences · 2022Article
- Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2.Biomedicines · 2022Article
- Incidence comparison of adverse events in patients with inflammatory bowel disease receiving different biologic agents: retrospective long-term evaluation.Intestinal research · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The biologic antitumor necrosis factor alpha (anti-TNFα) agents have revolutionised the treatment of inflammatory bowel disease (IBD). However, some patients experience primary nonresponse, loss of response, or intolerance. Therefore, introducing a newer class of therapy with a mechanism of action that acts on different inflammatory pathways involved in IBD pathogenesis is appealing. Vedolizumab is a fully humanised monoclonal antibody that selectively targets α4β7 integrin. Based on the results of the pivotal clinical GEMINI trials, vedolizumab was approved for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) refractory or intolerant to either conventional therapy or TNFα inhibitors. This review describes the efficacy, safety, and tolerability of vedolizumab reported in both randomized, controlled, clinical trials and from real-world experience in patients with UC and CD in order to identify its place in treatment algorithms for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.